Pharmacogenetics research in Brazil: a systematic review.
Pharmacogenomics
; 23(4): 263-275, 2022 03.
Article
em En
| MEDLINE
| ID: mdl-35187980
ABSTRACT
Aim:
Pharmacogenomics (PGx) is a rising scientific area in many countries, such as Brazil.Objectives:
To identify biomarkers, therapeutic areas, probe drugs and regions/ethnicities most studied in the country in order to guide future studies. Materials &methods:
Systematic review of 1060 studies (from 1968 to 2020) comprising 80 genes, six probe drugs and 3,819,233 individuals.Results:
MTHFR and HLA-A/B were the most studied genes and metoprolol and dextromethorphan the most studied probe drugs. Oncology was the most studied therapeutic area considering PGx biomarkers. The country's regions and ethnic groups were studied unevenly, with south/southeast and White people over-represented in respect to their demographic relevance, in detriment of the center-west/northeast/north and Black/mixed individuals.Conclusion:
Many of the gaps and possible paths to be covered to reach even PGx data are pointed out by this review.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Antígenos HLA-B
Tipo de estudo:
Systematic_reviews
Limite:
Humans
País/Região como assunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Pharmacogenomics
Assunto da revista:
FARMACOLOGIA
/
GENETICA MEDICA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Brasil